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Signaling through oncogenic PI3K/AKT kinase pathway is crucial to cell and organ growth. 
Phosphorylation by AKT has long been perceived as a key factor to enhance protein biosynthesis that 
enables cell growth and survival. Here, we report that HSF1, the master regulator of the proteotoxic stress 
response (PSR), is a new AKT substrate. Beyond mobilizing the PSR under heat shock, the AKT-
mediated HSF1 activation supports robust growth. In a mouse model of human megalencephaly, 
expression of a constitutively active PI3KCA suffices to drive brain overgrowth, and strikingly, it also 
provokes proteomic chaos including protein aggregation and amyloidogenesis. Deletion of Hsf1 in this 
 
 
model reduces the brain size and prolongs the mice survival. Furthermore, HSF1 maintains mitochondrial 
proteome homeostasis and prevents cell death by protecting the key mitochondrial chaperone HSP60 
from aggregation. Independently of its transcriptional activity, HSF1 sequesters amyloid oligomers away 
from HSP60 through physical interactions. Together, our findings unveil three novel aspects of HSF1 
biology: 1) HSF1 is a new substrate of AKT kinase; 2) HSF1 supports tissue overgrowth by balancing the 
protein quality and quantity; 3) HSF1 not only prevents amyloidogenesis but also suppresses amyloid-
induced cellular toxicity. 
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 1 
CHAPTER 1 
 INTRODUCTION 
1.1 Proteome Homeostasis and Human Diseases 
Proteome homeostasis (proteostasis) is a process that regulates the balance of cellular production, folding, 
and degradation of proteins within or outside the cells (Klaips, Jayaraj et al., 2018). It maintains cellular 
fitness by coordinating multiple interconnected pathways to control the fate of proteins starting from 
biosynthesis, to folding, and to degradation (Labbadia and Morimoto, 2015). Several key players have 
been known to maintain proteostasis. For instance, molecular chaperones or heat shock proteins (HSPs) 
are the main effectors to facilitate protein biosynthesis and protein folding (Kim, Hipp et al., 2013). The 
ubiquitin-proteasome system controls degradation of misfolded or unfolded proteins (Bett, 2016). The 
autophagy and lysosome pathways are responsible for clearing protein aggregates (Tanaka and Matsuda, 
2014). All these pathways cooperate with each other to maintain proteostasis and to keep cellular fitness. 
However, a variety of environmental challenges, such as extreme temperature, deprivation of nutrients 
and exposure to toxins or radiation, can disrupt proteostasis and elicit proteotoxic stress in cells (Klaips, 
Jayaraj et al., 2018). Constant perturbation of proteostasis can manifest in human pathologies including 
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neurodegenerative disorders, diabetes and cancer (Kaushik and Cuervo, 2015). For instance, failure of 
proteostasis can lead to accumulation of amyloid plaques and neurofibrillary tangles in brains, which are 
generally considered as the pathological hallmarks of Alzheimer’s disease (Scheper, Nijholt et al., 2011). 
It is thought that disruption of proteostasis increases protein misfolding and aggregation and exhausts the 
proteostatic mechanisms, leaving susceptible proteins –such as Ab amyloids in Alzheimer’s disease–at a 
greater risk for aggregation and amyloidogenesis (Regitz, Fitzenberger et al., 2016). During 
amyloidogenesis, certain misfolded proteins first form the intermediate structure soluble amyloid 
oligomers, which can further form insoluble amyloid fibrils with enriched β-sheet structures (Gremer, 
Scholzel et al., 2017). Recent studies suggest that soluble oligomers of Ab are more cytotoxic than 
insoluble Ab fibrils, which contribute to neuronal cell death and cognitive decline in Alzheimer’s disease 
patients. Researchers found that the level of Ab oligomers is elevated in cerebrospinal fluids and cortexes 
of the brains of Alzheimer’s disease patients (Georganopoulou, Chang et al., 2005). Furthermore, Ab 
oligomers induce neuronal cell death when they are introduced into the brains of aging rhesus monkeys 
(Geula, Wu et al., 1998). 
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Disruption of proteostasis is a common characteristic of neurodegenerative disorders. Besides 
Alzheimer’s disease, aggregation of specific proteins in degenerating brains is also found in Parkinson’s 
disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS) (Fernandez-Busquets, 2013). 
Ubiquitous accumulation of aggregated proteins, such as Ab-amyloid, a-synuclein and superoxide 
dismutase 1 (SOD1), in these diseases highlights the significance of proteostasis in neurodegenerative 
disorders (Ancsin, 2003).  
In addition, there is growing evidence implicating the decline of proteostasis as one of the contributors to 
the pathogenesis of diabetes. For instance, increased protein ubiquitination and reduced proteasomal 
activity is detected in the islets of type 2 diabetic patients (Bugliani, Liechti et al., 2013). Furthermore, 
dysregulation of chaperone network is detected during the progression of diabetes, which further 
promotes insulin resistance, loss of beta cell differentiation and apoptosis of beta cells (Chien, Aitken et 
al., 2010) (Chung, Nguyen et al., 2008) . 
Emerging evidence also reveals that proteotoxic stress is a novel hallmark of cancer (Donnelly and 
Storchova, 2015). Tumor cells need a high proteostatic capacity for basic survival and proliferation, since 
genetic instability within tumor cells and acid and hypoxic microenvironment outside tumor cells 
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constantly put them under proteotoxic stress conditions. For example, aneuploidy increases protein 
burden and numerous genetic mutations cause protein instability, which exacerbates the proteostasis 
imbalance (Sansregret and Swanton, 2017). Inhibitors that disrupt proteostasis, such as HSP90 inhibitors 
or proteasome inhibitors were shown to decrease tumor cell proliferation in animal models, and are 
currently in clinical trials for cancer therapy, which supports the importance of proteostasis to malignant 
transformation (Yang, Lee et al., 2017) (Kim, Lee et al., 2017). These studies have revealed a novel 
perspective of cancer. Much effort has been put to understand the mechanism and regulation of 
proteostasis in cancer. Full appreciation of the role of proteostasis will help us develop novel and 
improved cancer chemotherapeutics.  
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1.2 HSF1 is a Guardian of Proteostasis under Stress 
Molecular chaperons or Heat shock proteins (HSPs) are the main effectors to maintain proteome 
homeostasis (Morimoto, 2011). A small group of transcriptional factors named HSFs are controlling the 
induction of molecular chaperones or HSPs during proteotoxic stress conditions. There are nine HSFs 
paralogs – HSF1, 2, 3, 4, 5, X1, X2, Y1 and Y2 – identified in vertebrates (Akerfelt, Morimoto et al., 
2010). All the HSF proteins share three conserved functional domains: the N-terminal DNA binding 
domain (DBD), the trimerization domain enriched for hydrophobic heptad repeats (HR) and the C-
terminal transactivation domain (AD) (Vihervaara and Sistonen, 2014). HSFs bind to the heat shock 
element, an evolutionarily conserved DNA sequence consisting of a series of nTTCnGAAn via their 
DBDs under proteotoxic stress conditions (Huang, Wu et al., 2018). Among these HSFs, HSF1 is the 
master regulator of HSP induction in mammals. Genetic ablation of Hsf1 in MEFS abolish the induction 
of Hsps under proteotoxic stress conditions while deletion of Hsf2, Hsf3, Hsf4 in mice retain the Hsps 
induction, which highlights HSF1’s essential role in preserving proteostasis under stress conditions (Dai 
and Sampson, 2016).  
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Deletion of Hsf1 in mice causes prenatal lethality, due to placental defects, and female infertility (Dai and 
Sampson, 2016). Recent study showed that Hsf1 deficiency affects systemic body temperature regulation 
by increasing core body temperature (Ingenwerth, Noichl et al., 2016). In addition, sperms of Hsf1 
knockout mice lose motility after exposed to hyperthermia (Dai and Sampson, 2016). 
Although there are no other disease-related phenotypes caused by proteotoxicity are detected in Hsf1 
knockout mice under normal conditions, one group found that Hsf1 knockout mice had a significantly 
shortened lifespan compared to wide-type mice after infected with Rocky Mountain Laboratory (RML) 
prions (Steele, Hutter et al., 2008). However, surprisingly, the onset of pathological changes was observed 
at the same time in Hsf1 knockout and wide-type mice, which indicates that HSF1 has a protective role in 
the progression of prion disease (Steele, Hutter et al., 2008). Furthermore, in another adult-motor neuron 
disease mouse model – spinal and muscular atrophy (SBMA) caused by the expression of CAG repeats in 
the androgen receptor (AR) gene, HSF1 levels are highly correlated with the accumulation of pathogenic 
AR. High levels of pathogenic AR are detected in the spinal motor neurons with decreased HSF1 
expression. More importantly, deletion of Hsf1 in this SBMA mice model intensifies the accumulation of 
pathogenic AR and aggravates neurodegeneration phenotypes (Kondo, Katsuno et al., 2013). Similarly, 
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Hsf1 deficiency in a Huntington’s disease mouse model accelerates disease progression by increasing 
aggregation of mutant huntingtin (mHTT), whereas over-expression of a constitutively active form of 
HSF1 in the same mouse model ameliorates mHTT aggregation and extends mice lifespan (Hayashida, 
Fujimoto et al., 2010) (Fujimoto, Takaki et al., 2005). In a mouse model of Parkinson disease, Hsf1 is 
deleted in the midbrains of mice expressing a-synuclein (Kim, Wang et al., 2016). In contrast to Hsf1 
deficiency, over-expression of a constitutively active form of HSF1 in the human cells modeling 
Parkinson disease reduces cellular toxicity by decreasing a-synuclein aggregation (Liangliang, Yonghui 
et al., 2010). Regarding Alzheimer’s disease, HSF1 level is reduced in cerebellar Purkinje cells, a brain 
cell type that is decreased in Alzheimer’s disease patients and mouse model of Alzheimer’s disease. Over-
expression of a constitutively active form of HSF1 in the mouse model of Alzheimer’s disease recovers 
the cognitive defects associated with Alzheimer’s disease by reducing Ab-amyloid aggregation and 
restoring the number of cerebellar Purkinje cells (Jiang, Wang et al., 2013). Moreover, activation of HSF1 
pharmacologically by HSP90 inhibitors decreases Ab-amyloid aggregation and alleviates memory loss in 
a mouse model of Alzheimer’s disease (Chen, Wang et al., 2014). Similar to Alzheimer’s disease, HSF1 
activity is diminished in the motor neurons of amyotrophic lateral sclerosis (ALS) patients and the mouse 
 8 
model of ALS (Batulan, Shinder et al., 2003). Further deletion of Hsf1 in a mouse model of ALS 
escalates aggregation of TDP-43, which is also associated with ALS in addition to SOD-1, and 
exacerbates the ALS-associated phenotypes, whereas overexpression of HSF1 in this mouse model 
reduces cellular toxicity by preventing TDP-43 from aggregating (Chen, Mitchell et al., 2016). 
Accumulated evidence has demonstrated that HSF1 promotes tumorigenesis and tumor progression. Two 
independent studies first sowed that genetic deletion of Hsf1 in mice impaired tumorigenesis in Trp53 
deficient mice and chemical-induced skin carcinogenesis (Min, Huang et al., 2007) (Dai, Whitesell et al., 
2007). In addition, Hsf1 deficiency suppressed carcinogenesis caused by loss of tumor suppressor gene 
Nf1 and impaired the lung metastasis in MMTV-HER2/Neu transgenic mice (Dai, Santagata et al., 2012) 
(Xi, Hu et al., 2012). Also, another study pointed out that HSF1 largely remained in nuclear in malignant 
breast cancers compared to normal breast cells, which indicates HSF1 was active in malignant tumors 
(Santagata, Hu et al., 2011). Furthermore, HSF1 is found to stay mainly in nuclear in many other types of 
cancers, including cervical cancer, colon cancer, lung cancer, pancreatic cancer, prostate cancer, and 
meningioma, which indicates HSF1 is highly mobilized in these cancers (Dai and Sampson, 2016). 
Together, HSF1 is constitutively activated in cancer cells and HSF1 activation is indispensable for 
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tumorigenesis and tumor progression (Liao, Xue et al., 2015) (Mendillo, Santagata et al., 2012) (Tong, Li 
et al., 2018). Recently, researchers started to unveil the underlying mechanisms of HSF1 activation in 
these cancers and how HSF1 regulates proteostasis in tumor cells.  
So, these findings emphasize that HSF1 critically guards proteostasis not only in physiological conditions 
but also in pathological conditions such as neurodegenerative disorders and cancers. Our previous study 
showed inhibition of HSF1 in tumor cells elicits global protein ubiquitination, aggregation, and even 
more strikingly, accumulation of amyloids, which is toxic to tumor cells. However, the most important 
question of how HSF1 suppresses amyloidogenesis to guard proteostasis remains unanswered in the field. 
Does HSF1 suppress amylodogenesis through its transcriptional regulation of molecular chaperons? Or, 
can HSF1 suppress amyloidogenesis independent of its transcriptional activity? In this project, we start 
addressing these key questions. 
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1.3 HSF1 Activation is a Multi-step Process 
Upon proteotoxic stress, HSF1 undergoes trimerization, nuclear translocation, phosphorylation, and DNA 
binding, leading to its activation (Akerfelt, Morimoto et al., 2010). It is commonly believed that HSF1 is 
repressed by HSP90 complexes under normal conditions whereas it is released from this repression after 
HSP90 is titrated away by misfolded proteins induced by proteotoxic stress conditions (Vihervaara and 
Sistonen, 2014). Following trimerization and nuclear translocation, HSF1 is phosphorylated on multiple 
sites by different kinases, several of which are reported to promote HSF1 activity. For instance, 
phosphorylation of HSF1 at S230 site by CAMK2A or DAPK increases HSF1 activity (Holmberg, 
Hietakangas et al., 2001). Also, phosphorylation at S320 site by protein kinase A and at S419 site by 
polo-like kinase 1 both activates HSF1 (Zhang, Murshid et al., 2011) (Kim, Yoon et al., 2005). 
Furthermore, some phosphorylation events are associated with inhibition of HSF1, including S121 
phosphorylation by AMPK (Dai, Tang et al., 2015), T142 phosphorylation by CK2 (Soncin, Zhang et al., 
2003), S303 phosphorylation by MAPK and S363 phosphorylation by protein kinase C (PKC) (Dai, 
Frejtag et al., 2000) Ultimately, HSF1 trimers bind to heat shock elements in the promote regions of HSPs 
through the N-terminal DBD. However, unlike conventional proteotoxic stress conditions, tumor cells 
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may directly regulate HSF1 activity through oncogenic signals. Several studies have elucidated how 
HSF1 is regulated by oncogenic signaling in cancer.  
AMP-activated protein kinase (AMPK) is a metabolic tumor suppressor (Rourke, Hu et al., 2018). AMPK 
functions as an energy sensor, closely monitoring the AMP/ATP or ADP/ATP ratios in the cells 
(Ronnebaum, Patterson et al., 2014). When cells demand acute energy, AMPK is activated to generate 
more ATP by stimulating fatty acid oxidation and to inhibit anabolic processes that consume ATP (Wang, 
Xin et al., 2017). Thus, AMPK is a therapeutic target for metabolic diseases including type 2 diabetes 
(Umezawa, Higurashi et al., 2017). Of note, AMPK is activated by an upstream kinase, LKB1, which is a 
well-known tumor suppressor (Kone, Pullen et al., 2014). LKB1 loss-of-function mutations have been 
found in many different types of cancer, including lung adenocarcinomas, squamous cell carcinomas and 
cervical carcinomas (Zhou, Zhang et al., 2014). AMPK is a key player in mediating the tumor-
suppressive role of LKB1. In a PTEN+/- mouse tumor model, tumor progression is accelerated by LKB1 
mutation that decreases LKB1 level, whereas tumor progression is delayed by AMPK activators that 
enhance AMPK activity (Huang, Wullschleger et al., 2008). In addition, in a lymphoma mouse model 
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expressing transgenic c-Myc, deletion of Ampka1, which is encoding for the only catalytic subunit 
expressed in B cells, promotes the lymphoma development (Zadra, Batista et al., 2015).  
Interestingly, our recent study showed that AMPK physically interacts with and phosphorylates HSF1 at 
S121 site under metabolic stress (Dai, Tang et al., 2015). This phosphorylation inhibits HSF1 activity 
partly via impairing its nuclear translocation. Both glucose deprivation and metformin treatment block 
HSF1 activation by activating AMPK. Importantly, both glucose deprivation and metformin treatment 
diminish HSF1 activity in tumor cells, disrupting tumor proteostasis and inducing apoptosis. In contrast, 
knocking down AMPK in tumor cells enhances HSF1 activity and helps tumor cells adapt to stressful 
tumor micro-environments. This finding indicates that HSF1 is directly regulated by the tumor-
suppressive AMPK and suggests that HSF1 activation in tumors may be partly due to loss of LKB1 and 
inactivation of AMPK.  
In addition to tumor suppressor signaling, another recent study revealed that the oncogenic RAS/MEK 
signaling maintains tumor proteostasis via activating HSF1. The RAS/MEK signaling cascade controls 
cell growth, differentiation, and survival (Zhong, 2016). Hyper-activation of this signaling pathway is 
frequently associated with human cancer, leading to tumor development (Martinelli, Morgillo et al., 
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2017). Activating somatic mutations in the components of this signaling such as RAS, RAF, MEK genes 
are identified in nearly 30% of all human cancers (Wong, 2009).  
In tumor cells, inhibition of RAS/MEK signaling inactivates HSF1 through blockade of HSF1 S326 
phosphorylation, leading to protein aggregation and amyloidogenesis (Tang, Dai et al., 2015). 
Interestingly, it is MEK, not ERK, that directly binds to and phosphorylates HSF1 at S326 site. ERK has 
long been regarded as the main downstream effector of RAS/MEK signaling. Instead, MEK regulates 
HSF1 activity through phosphorylation of S326 site whereas ERK impairs this process through inhibitory 
phosphorylation of MEK at T292 and T386 sites (Tang, Dai et al., 2015). These findings unveil a novel 
mechanism by which tumor cells constitutively mobilize HSF1 through hyper-activation of oncogenic 
pathways such as RAS/MEK signaling.  
Despite these novel findings, many questions about how HSF1 is constitutively mobilized in tumor cells 
remain. Particularly, it is still unclear whether other oncogenic pathways also directly cause constitutive 
activation of HSF1 within cancer cells. In this project we set out to address this important question.  
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CHAPTER 2 
PI3K/AKT SIGNALING ACTIVATES HSF1 TO PRESERVE PROTEOSTASIS AND SUSTAIN 
GROWTH 
2.1 Summary 
Through stimulation of the mTORC1-mediated translation, PI3K/AKT signaling promotes both cellular 
and organismal growth. Here, we report that heat-shock factor 1 (HSF1), the master regulator of the 
proteotoxic stress response and a key player in maintaining proteostasis, is a new physiological substrate 
for AKT. Under heat stress, AKT physically interacts with HSF1, phosphorylates HSF1 at Ser230 site, 
and regulates HSF1 DNA binding activity. Beyond mobilizing the HSR/PSR under heat shock, the AKT-
mediated HSF1 activation supports robust growth. In a mouse model of human megalencephaly, 
expression of a constitutively active PI3KCA (PI3KCA*) suffices to drive brain overgrowth. Importantly, 
concurrent Hsf1 deletion reduces brain size. Mechanistically, constitutive activation of PI3K signaling in 
the brains induces global protein ubiquitination and, strikingly, amyloidogenesis, including Ab amyloids 
closely associated with Alzheimer’s disease in humans. Furthermore, Hsf1 deficiency markedly heightens 
amyloid levels. Despite elevated amyloid levels, we do not detect apparent apoptosis in Hsf1-proficient 
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brains expressing PI3KCA*. By contrast, marked apoptosis is only induced in Hsf1-deficient brains 
expressing PI3KCA*. Thus, our results suggest that HSF1 is necessary for robust growth by balancing 
both protein quantity and quality, thereby preserving proteostasis and impeding amyloidogenesis. More 
importantly, our data reveal that HSF1 prevents HSP60 aggregation and maintains the mitochondrial 
proteome homeostasis to promote the overgrowth driven by PI3K/AKT signaling. Through physical 
interaction, HSF1 sequesters amyloid oligomers away from HSP60, and surprisingly, HSF1 mutant 
lacking transcriptional activity also segregates amyloid oligomer from and rescues HSP60. Our findings 
unveil a novel biological function of HSF1 in guarding mitochondria proteostasis and protecting cells 
from the toxicity induced by amyloids.  
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2.2 Introduction 
Cells are constantly exposed to various types of biological stressors, such as hyperthermia, nutrient 
deprivation, toxins, and radiation. As a result, cells initiate distinct biological responses to survive theses 
stressful conditions (Swan and Sistonen, 2015). Among these environmental insults, proteotoxic stressors 
often result in accumulation of unfolded or misfolded proteins. Proteotoxic stress is mitigated by a 
cellular defensive mechanism called the heat-shock response (HSR) or proteotoxic stress response (PSR) 
(Anckar and Sistonen, 2011). Heat-shock proteins (HSPs) or molecular chaperones act as the major 
effectors of the PSR or HSR, which facilitate protein folding, trafficking and degradation to maintain 
proteome homeostasis, or proteostasis, and ensure cell survival under proteotoxic stress conditions (Dai 
and Sampson, 2016).  
In vertebrates, a small group of transcription factors governing the HSR/PSR are called heat-shock factors 
(HSFs) (Vihervaara and Sistonen, 2014). Among them, heat-shock factor 1 (HSF1) is known as the 
master regulator of the HSR/PSR, since mice without Hsf1 have no induction of Hsp transcription under 
proteotoxic stress conditions (Hayashida, Inouye et al., 2006). During proteotoxic stress, HSF1 undergoes 
multiple steps to achieve activation, including phosphorylation, trimerization, nuclear translocation, 
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phosphorylation and DNA binding (Santagata, Hu et al., 2011). However, the process is still not fully 
understood. HSF1 binds to the genomic heat-shock elements, an evolutionarily conserved DNA sequence 
consisting of nTTCnGAAn, to induce HSPs’ transcription under proteotoxic stress conditions 
(Vihervaara, Sergelius et al., 2013). In addition, HSF1 has been implicated in development, insulin 
signaling, tumor initiation and progression (Vihervaara and Sistonen, 2014). HSF1 acts as a pro-
oncogenic factor and is regulated by oncogenic and tumor-suppressive signaling pathways. It has become 
increasingly apparent that HSF1 is indispensable to tumor cell growth and survival (Dai and Sampson, 
2016). Since phosphorylation is important to HSF1 activation, recent studies unveiled that 
phosphorylation by oncogenic pathways contributes to HSF1 constitutive activation in tumor cells. 
Phosphorylation of Ser326 site of HSF1 by onco-protein MEK1 or MEK2 activates HSF1 to protect 
proteostasis and suppress amyloidogenesis in tumor cells (Tang, Dai et al., 2015). Also, HSF1 activation 
is suppressed by phosphorylation of Ser121 site mediated by the tumor-suppressive AMPK (Dai, Tang et 
al., 2015).  
Like RAS/MEK signaling, PI3K/AKT signaling is another important oncogenic pathway controlling cell 
growth and survival. PI3K heterodimers, consisting of p110 catalytic and p85 regulatory subunits, and are 
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activated by growth factor receptor tyrosine kinases (RTKs) through phosphorylation of adaptor proteins 
including IRS1/IRS2 (Engelman, Luo et al., 2006). Phosphorylation of these adaptor proteins releases the 
inhibitory effect of the p85 regulatory subunit on the p110 catalytic subunit, which allows PI3K 
heterodimers translocate to the plasma membrane. p110 subunit phosphorylates phosphatidylinositol 
(4,5)-trisphosphate (PIP2) to generate phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PTEN, the 
primary negative regulator of this signaling pathway, dephosphorylates PIP3 to PIP2 (Wentink, Dalm et 
al., 2017). PIP3 activates AKT through PDK1, and subsequently AKT regulates hundreds of downstream 
targets, including GSKs, FoxO transcription factors and TSC2 to promote cell growth and survival 
(Manning and Toker, 2017). Particularly, AKT phosphorylates and inhibits TSC2. This AKT-mediated 
TSC2 inhibition subsequently activates mTOR complex 1(mTOCR1), leading to enhanced protein 
biosynthesis that enables cell growth and survival (Laplante and Sabatini, 2012).  
Here, we report that PI3K/AKT signaling activates the HSR/PSR. AKT phosphorylates HSF1 at Ser230, 
leading to HSF1 activation. Although constitutive activation of PI3K/AKT signaling inevitably creates 
proteotoxic stress and destabilizes the proteome, HSF1 plays a critical role in mitigating amyloidogenesis 
and, importantly, maintaining the mitochondrial proteostasis by blocking amyloid-induced HSP60 
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aggregation, which prevents apoptosis to support overgrowth. To our surprise, HSF1 protects HSP60 by 
physically interacting with amyloid oligomers. Thus, beyond shifting the canonical view of HSF1 as a 
transcription factor, our findings also suggest that HSF1 physically preserves proteostasis.  
 
 
 
 
 
 
 
 
 
 
 
 
 20 
2.3 Results 
2.3.1 PI3K/AKT Pathway regulates the PSR 
Oncogenic signaling pathways play a key role in regulating HSF1 activation through phosphorylation. 
For instance, MEK and ERK oppositely regulate HSF1 activation and MEK directly phosphorylates the 
Ser326 site of HSF1 (Tang, Dai et al., 2015). To explore whether other oncogenic pathways also regulate 
the HSR/PSR, we focused on PI3K/AKT signaling. First, we examined its response to heat stress in 
HEK293T cells (Morimoto, 1991). Exposure to heat-shock elevated the phosphorylation of AKT, the key 
component of PI3K/AKT signaling. Phosphorylation of both Ser473 and Tyr308 of AKT were increased, 
which signifies the active state of PI3K/AKT signaling pathway (Fig 1 A, B).  
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Figure 1. PI3K/AKT pathway regulates the PSR 
(A) HS activates PI3K/AKT signaling. HEK293T cells were treated with HS at 43°C for 30min. Flow 
cytometry confirmed pAKT T308 and pAKT S473 levels were increased after HS (mean of the geometric 
means of fluorescence intensity±SD, n=3 independent experiments, Student’s t test). Non-HS: non-heat 
shock condition. HS: heat shock condition.  
(B) HS activates PI3K/AKT signaling. A2058 melanoma cells were treated with HS at 43°C for 30min. 
IF staining confirmed that pAKT T308 and pAKT S473 levels were increased after HS. Non-HS: non-
heat shock condition. HS: heat shock condition. Scale bar is 10µm.  
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Figure 1 continued 
(C) Inhibition of PI3K/AKT signaling blocks the induction of HSPs by HS. A2058 cells were pre-treated 
with 20µM LY29402 (LY), 20µM MK2206 (MK) or 20µM RG7440 (RG) for 3 hours followed by HS 
and 4-hr recovery at 37oC with the inhibitors. mRNA levels were quantitated by qRT-PCR (mean±SD, 
n=3 independent experiments, one-way ANOVA). LY: LY29402. MK: MK2206. RG: RG7440. Non-HS: 
non-heat shock condition. HS: heat shock condition.  
(D) Inhibition of PI3K/AKT signaling blocks the induction of HSPs by HS. NIH3T3 cells stably 
expressing the HSE-EGFP reporter were treated with 20µM LY29402, 20µM MK2206 or 20µM RG7440 
for 3 hours followed by HS and overnight recovery at 37oC with the inhibitors. Immunoblotting 
confirmed that protein levels of HSP72 and HSP25 were decreased after LY29402, MK2206 and RG7440 
treatment during HS. LY: LY29402. MK: MK2206. RG: RG7440. Non-HS: non-heat shock condition. 
HS: heat shock condition. 
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Figure 1 continued 
(E) AKT1, AKT2, or AKT3 sufficiently activates HSF1. The dual HSF1 reporter system, comprising a 
heat shock response element (HSE)-driven secreted embryonic alkaline phosphatase (SEAP) plasmid and 
a CMV-driven Gaussia luciferase (GLuc) plasmid, was transfected into HEK293T cells. Cells were also 
transfected with constitutively active AKT1, AKT2 or AKT3 plasmids and were measured for reporter 
activities after 72 hours (mean ±SD, n=3 independent experiments, one-way ANOVA). Reporter assays 
confirmed that HSF1 was activated by constitutively active AKT1, AKT2 or AKT3.  
(G) Loss of PTEN increases HSF1 reporter activity and this increase can be blocked by AKT inhibitors. 
PTEN deficient cells were transfected with the dual HSF1 reporter plasmids. After 24 hours, cells were 
treated with 20µM MK2206 or 20µM RG7440 for another 24 hours. Reporter assays confirmed that 
HSF1 reporter activities were increased in PTEN-deficient cells and they were suppressed by MK2206 
and RG7440 treatment. (mean ±SD, n=3 independent experiments, one-way ANOVA) MK: MK2206. 
RG: RG7440. SCR: siControl. 
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Figure 1 continued 
(F) AKT1 increases the mRNA levels of HSP72 and HSP27. HEK293T cells were transfected with 
constitutively active AKT1 plasmid for 72 hours. mRNA levels were quantitated by qRT-PCR 
(mean±SD, n=3 independent experiments, Student's t-test). qRT-PCR confirmed that mRNA levels of 
HSP72 and HSP27 were increased after AKT1 overexpression. 
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To test whether PI3K/AKT pathway regulates the HSR/PSR, we utilized MK2206 and RG7440, two 
specific AKT inhibitors (Winder, Unno et al., 2017) (Blake, Xu et al., 2012), and LY294002, a PI3K 
inhibitor (Trisciuoglio, Iervolino et al., 2005). All the inhibitors impaired the HS-induced transcription of 
HSPs genes and the production of HSP proteins (Fig 1 C, D). On the other hand, over-expression of all 
three isoforms of AKT (AKT1, AKT2, AKT3) proteins increased the transcriptional  
activity of HSF1 and mRNA levels of HSPs genes (Fig 1 E, F), which indicates that PI3K/AKT signaling 
activates the HSF1-mediated HSR/PSR and AKT directly regulates HSF1 activity. PTEN is a well-known 
negative regulator of the PI3K/AKT pathway (Kechagioglou, Papi et al., 2014). So, unsurprisingly, in 
PTEN-deficient cells, HSF1 activity was increased and this elevation could be suppressed by AKT 
inhibitors (Fig 1 G). These results further support that the PI3K/AKT signaling pathway positively 
regulates the HSF1 activity. 
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2.3.2 AKT physically interacts with HSF1 and phosphorylates Ser230 to activate HSF1 
To further test whether AKT, not PI3K, directly interacts with HSF1, we carried out co-
immunoprecipitation (coIP) experiments to detect endogenous interactions between AKT or PI3K and 
HSF1. HSF1 proteins were co-precipitated from lysates of HEK293T cells with AKT proteins, but not 
with PI3K proteins. Heat shock caused a markedly increased coIP of HSF1 and AKT (Fig 2 A), which 
demonstrates a stress-inducible AKT-HSF1 interaction. The electrophoretic mobility shift of HSF1 after 
heat shock suggests induced HSF1 phosphorylation (Fig 2 A). To use a different approach to examine 
whether HSF1 and AKT are in direct contact, we utilized the Proximity Ligation Assay (PLA) (Tang and 
Dai, 2017). Using two species-specific secondary antibodies conjugated with DNA oligonucleotides, PLA 
assay can transform protein-protein interactions in close proximity into DNA signals, which can be 
further detected by microscope or flow cytometry (Tang, Lu et al., 2014). We detected PLA signal in 
HeLa cells under both heat shock and non-heat shock conditions (Fig 2 B), whereas heat shock clearly 
intensified the PLA signals. These findings strongly support a direct association of HSF1 and AKT 
induced by heat shock.  
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Figure 2. AKT physically interacts with HSF1 and phosphorylates Ser230 to activate HSF1 
(A) AKT physically interacts with HSF1. Endogenous HSF1 proteins were co-precipitated with AKT 
proteins from HEK293T cells after HS at 43°C for 30min. WCL: whole cell lysate. Immunoblotting 
confirmed that a direct association of HSF1 and AKT induced by heat shock. Non-HS: non-heat shock 
condition. HS: heat shock condition.  
(B) AKT physically interacts with HSF1. Endogenous AKT1-HSF1 interactions were detected by PLA in 
HeLa cells using a rabbit anti-AKT1 antibody and a mouse anti-HSF1 antibody. PLA staining confirmed 
that a direct association of HSF1 and AKT induced by heat shock. Non-HS: non-heat shock condition. 
HS: heat shock condition. Scale bar is 10µm. 
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Figure 2 continued 
(C) Schematic description of AKT phosphorylation motif. 
(D) AKT1, AKT2 and AKT3 phosphorylate HSF1 at Ser230 site in vitro. 100ng recombinant AKT 
proteins were incubated with 400ng recombinant His-HSF1 proteins at RT for 30min. HSF1 
phosphorylation was detected by immunoblotting. Blotting confirmed that AKT1, AKT2 and AKT3 
proteins all phosphorylate HSF1 at Ser230 site, and MK2206 and RG7440 blocks this phosphorylation.  
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Figure 2 continued 
(E) Inhibition of PI3K/AKT signaling suppresses the induction of pHSF1 S230 by HS. A2058 cells were 
treated with 20µM LY29402, 20µM MK2206 or 20µM RG7440 for 3 hours followed by HS and proteins 
were detected by immunoblotting. Blotting confirmed that levels of pHSF1 S230 were decreased after 
LY29402, MK2206 and RG7440 treatment under both HS and non-HS conditions. LY: LY29402. MK: 
MK2206. RG: RG7440. Non-HS: non-heat shock condition. HS: heat shock condition.  
(F) Loss of PTEN increases pHSF1 S230. Proteins were detected by immunoblotting in HEK293T cells 
expressing PTEN-targeting shRNAs. Blotting confirmed that the level of pHSF1 S230 was increased in 
PTEN-deficient cells. shScram: shRNA Control.  
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Figure 2 continued 
(G) HSF1S230A mutants have impaired transcriptional activity, and AKT inhibitors impair the 
transcriptional activity of HSF1WT but not the transcriptional activity of HSF1S230A. HEK293T cells stably 
expressing HSF1-targeting shRNAs were transfected with the dual HSF1 reporter plasmids. Cells were 
also co-transfected with HSF1WT or HSF1S230A plasmids and after 48 hours cells were pre-treated with 
20µM MK2206 for 3 hours followed by HS and 24-hour recovery. Then cells are measured for the 
reporter activities (mean ±SD, n=3 independent experiments, one-way ANOVA). Reporter assays 
confirmed that HSF1 reporter activities were decreased in HSF1S230A-transfected cells compared to 
HSF1WT-transfected cells under both HS and non-HS conditions. HSF1 reporter activities in HSF1WT-
transfected cells but not in HSF1230A-transfected cells were suppressed by MK2206 and RG7440 
treatment. Non-HS: non-heat shock condition. HS: heat shock condition. 
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We performed bioinformatics analysis of the human HSF1 protein sequence and at residue 230 we found 
a putative AKT substrate motif YSRQFS (Fig 2 C). A growing body of literature has proposed that AKT 
phosphorylates the consensus motif R-X-R-X-X-pS/pT, where X could be any amino acid residue and pS 
or pT represents either phosphorylated serine or threonine (Voukkalis, Koutroumani et al., 2016). Thus, 
we hypothesized that AKT likely directly phosphorylates HSF1 at Ser230. In order to test this, we first 
incubated recombinant human HSF1 proteins with either recombinant active AKT1, AKT2 or AKT3 
proteins in the presence or absence of AKT inhibitors (MK2206 and RG7440). All active AKT proteins 
phosphorylated HSF1 in vitro in the absence of AKT inhibitors, as detected by the specific pHSF1 S230 
antibody, which indicates that Ser230 is an AKT phosphorylation site (Fig 2 D). We verified the 
specificity of this pHSF1 Ser230 antibody using Hsf1 +/+ and -/- MEFs. Ser230 phosphorylation of 
HSF1 was increased in Hsf1 +/+ MEFs cells following HS, whereas no Ser230 phosphorylation of HSF1 
was detected in Hsf1 -/- MEFs in either HS or non-HS conditions (data not shown). Either PI3K inhibitor 
or AKT inhibitor impaired Ser230 phosphorylation of HSF1 under both HS and non-HS conditions in 
vivo (Fig 2 E), and in PTEN-deficient cells, phosphorylation of HSF1 Ser230 was significantly increased 
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(Fig 2 F). Together, both in vitro and in vivo findings indicate that AKT directly phosphorylates HSF1 at 
Ser230.  
Under proteotoxic stress, HSF1 undergoes a series of phosphorylation events, among which 
phosphorylation of Ser326 site is one key event leading to HSF1 activation (Morimoto, 2011). In contrast, 
how phosphorylation of Ser230 site affects HSF1 activity still remains elusive. Thus, we mutated serine 
230 site to alanine and examined the transcriptional activity of this HSF1S230A mutant. HSF1S230A mutants 
displayed impaired transcriptional activities after transfected into HSF1-deficient HEK293T cells. 
Moreover, AKT inhibitors reduced the activity of HSF1WT but not the activity of HSF1S230A in both non-
HS and HS conditions (Fig 2 G), which demonstrates that phosphorylation of Ser230 site is important for 
HSF1 activation by AKT.  
 
 
 
 
 
 33 
2.3.3 PI3K/AKT Signaling regulates HSF1 DNA Binding Ability  
HSF1 binding to DNA is the crucial step for HSF1 activation (Morimoto, 2014). In an effort to study 
whether PI3K/AKT signaling regulates HSF1 DNA-binding ability, we employed the chromatin-IP 
(ChIP) technique. As anticipated, HSF1 binding to both the HSP72 and HSP27 promoters were markedly 
increased following AKT1 overexpression in HEK293T cells (Fig 3 A). In contrast, both AKT inhibitors 
(MK2206 and RG7440) decreased HSF1 binding to the HSP72 promoter (Fig 3 B), which demonstrates 
that PI3K/AKT signaling is both sufficient and necessary to regulate HSF1-DNA binding. In addition, in 
PTEN-deficient HEK293T cells HSF1-DNA binding was heightened, and this elevation was suppressed 
by AKT inhibitors (Fig 3 C). These results offer compelling evidence that PI3K/AKT signaling positively 
regulates HSF1-DNA binding. Next, we investigated the DNA binding ability of HSF1S230A mutants. 
HSF1S230A mutants displayed impaired binding to either the HSP72 promoter or HSP27 promoter after 
transfected into HSF1-deficient HEK293T cells (Fig 3 D), which indicates that phosphorylation of Ser230 
site by AKT is important to the DNA binding of HSF1.  
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Figure 3. PI3K/AKT pathway regulates HSF1 DNA binding ability but not HSF1 nuclear translocation 
(A) AKT1 increases HSF1 binding to the HSP72 and HSP27 promoters. HSF1 ChIP assays were 
performed using HEK293T cells transfected with LACZ or AKT1 plasmids for 72 hours. The results were 
normalized against the values of IgG controls (mean ±SD, n=3 independent experiments, one-way 
ANOVA). qPCR confirmed that AKT1 increases HSF1 binding to the HSP72 and HSP27 promoters.  
(B) Inhibition of PI3K/AKT signaling decreases HSF1 binding to the HSP72 promoter. ChIP assays were 
performed using HEK293T cells treated with 20µM MK2206 or 20µM RG7440 for overnight. The results 
were normalized against the values of IgG controls (mean ±SD, n=3 independent experiments, one-way 
ANOVA). qPCR confirmed that MK2206 and RG7440 decreases HSF1 binding to the HSP72 promoter.  
(C) Loss of PTEN increases HSF1 binding to the HSP72 promoter and this increase can be blocked by 
AKT inhibitors. HSF1 ChIP assays were performed using HEK293T cells stably expressing PTEN-
targeting shRNAs treated with DMSO or 20µM MK2206 for overnight. The results were normalized 
against the values of IgG controls (mean ±SD, n=3 independent experiments, one-way ANOVA). qPCR 
confirmed that HSF1 binding to the HSP72 promoter was increased in PTEN-deficient cells and MK2206 
blocked this. MK: MK2206. 
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Figure 3 continued  
(D) HSF1S230A mutants have impaired binding ability to the HSP72 and HSP27 promoters. HSF1 ChIP 
assays were performed using HSF1-deficient HEK293T cells transfected with HSF1WT or HSF1S230A 
plasmids for 72 hours. The results were normalized against the values of IgG controls (mean ±SD, n=3 
independent experiments, one-way ANOVA). qPCR confirmed that HSF1 binding to HSP72 and HSP27 
promoters were decreased in HSF1S230A transfected HEK293T cells compared to HSF1WT transfected 
HEK293T cells.  
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Figure 3 continued  
(E) Inhibition of PI3K/AKT signaling does not affect HSF1 nuclear translocation. A2058 cells were pre-
treated with 20µM LY29402 or 20µM MK2206 for 3 hours followed by HS. Blotting confirmed that 
LY29402 and MK2206 did not impair HSF1 nuclear translocation under both HS and non-HS conditions. 
LY: LY29402. Non-HS: non-heat shock condition. HS: heat shock condition. C: cytoplasmic fraction. N: 
nuclear fraction.  
(F) HSF1S230A mutants have the same nuclear translocation ability as HSF1WT. HSF1-deficient HEK293T 
cells were transfected with HSF1WT or HSF1S230A plasmids for 72 hours followed by HS. Immunoblotting 
confirmed that nuclear translocation of HSF1S230A mutants was not affected. Non-HS: non-heat shock 
condition. HS: heat shock condition. C: cytoplasmic fraction. N: nuclear fraction. 
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HSF1 activation is a multi-step process, including phosphorylation, nuclear translocation, and DNA 
binding. Next, we investigated whether PI3K/AKT pathway regulates HSF1 nuclear translocation, a 
prerequisite for its DNA binding. As predicted, heat shock induced HSF1 proteins to translocate from the 
cytoplasm to the nucleus (Fig 3 E). Interestingly, neither LY294002 nor MK2206 impeded this process 
(Fig 3 E). LDH and LAMIN A/C were used as the cytoplasmic and nuclear fraction marker respectively. 
Also, HSF1S230A mutants displayed normal nuclear translocation after transfected into HSF1-deficient 
HEK293T cells (Fig 3 F). Thus, we conclude that PI3K/AKT signaling positively regulates HSF1 DNA 
binding, but does not affect HSF1 nuclear translocation. 
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2.3.4 AKT competes with CaMKII and DAPK to phosphorylate HSF1 
Ca2+/calmodulin-dependent protein kinase (CaMKII) and death-associated protein kinase (DAPK) have 
also been reported to phosphorylate HSF1 at Ser230 site (Holmberg, Hietakangas et al., 2001) 
(Benderska, Ivanovska et al., 2014). In order to understand how all three kinases, CaMKII, DAPK and 
AKT, interact with HSF1, we first tested that both CaMKII and DAPK indeed phosphorylate HSF1 at 
Ser230 in vitro. Recombinant HSF1 proteins were incubated with recombinant active CaMKII or DAPK 
proteins in vitro. Both CaMKII and DAPK proteins phosphorylated HSF1 proteins in vitro, as detected by 
the pHSF1 Ser230 antibody. (Fig 4 A) Also, phosphorylation of HSF1 by DAPK was blocked by the 
DAPK inhibitor (TC-DAPK 6) (Fig 4 B). In addition, knocking down either CaMKII or DAPK impaired 
HSF1 Ser230 phosphorylation in vivo (Fig 4 C D). Together, these in vitro and in vivo findings 
demonstrated that both CaMKII and DAPK phosphorylate HSF1 at serine 230 site. Then, we 
hypothesized that AKT must compete with CaMKII and DAPK to phosphorylate HSF1 at Ser230 in vivo. 
To test our theory, we utilized PLA to investigate HSF1-AKT interactions with the deficiency of either 
CaMKII, DAPK or both. PLA signals was measured by flow cytometry. Knocking down either CaMKII 
or DAPK increased the HSF1-AKT interaction, and knocking down both further intensified it (Fig 4 E), 
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which strongly supports that AKT competes with CaMKII and DAPK to phosphorylate HSF1 at Ser230 
in vivo.   
 
 
 
Figure 4. AKT competes with CaMKII and DAPK to phosphorylate HSF1 
(A) Both CaMKII and DAPK phosphorylate HSF1 at Ser230 site. 100ng recombinant CaMKII or DAPK 
proteins were incubated with 400ng recombinant His-HSF1 proteins at RT for 30min. HSF1 
phosphorylation was detected by immunoblotting. Blotting confirmed that pHSF1 Ser230 levels were 
increased when HSF1 proteins were incubated with either recombinant CaMKII or DAPK proteins.  
(B) DAPK phosphorylate HSF1 at Ser230 site in the absence of DAPK inhibitor. 100ng recombinant 
CaMKII or DAPK proteins were pre-incubated with the DAPK inhibitor (TC-DAPK 6) followed by 
incubation with 400ng recombinant His-HSF1 proteins at RT for 30min. HSF1 phosphorylation was 
detected by immunoblotting. Blotting confirmed that pHSF1S230 levels were increased when HSF1 
proteins were incubated with DAPK proteins and DAPK inhibitors blocked it. 
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Figure 4 continued  
(C) CaMKII phosphorylates HSF1 at Ser230 site in vivo. Proteins were detected by immunoblotting in 
HEK293T cells transfected with siRNAs targeting CaMKII. Blotting confirmed that pHSF1S230 levels 
were decreased following CaMKII knockdown. 
(D) DAPK phosphorylates HSF1 at Ser230 site in vivo. Proteins were detected by immunoblotting in 
HEK293T cells transfected with siRNAs targeting DAPK. Blotting confirmed that pHSF1S230 levels 
were decreased following DAPK knockdown. 
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Figure 4 continued  
(E) AKT competes with DAPK and CaMKII to phosphorylates HSF1 at Ser230 site in vivo. Endogenous 
AKT1-HSF1 interactions were detected by PLA in HEK293T cells transfected with siRNAs targeting 
either CaMKII, DAPK or both. PLA signals were captured by flow cytometry (mean of the geometric 
means of fluorescence intensity±SD, n=3 independent experiments, one-way ANOVA). Flow cytometry 
confirmed that association of AKT with HSF1 was enhanced when either DAPK or CaMKII was knocked 
down. Knockdown of both DAPK and CaMKII further increased the interaction between AKT and HSF1.  
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2.3.5 AKT activates HSF1 independent of MEK 
Our recent study proposed that MEK phosphorylates HSF1 at Ser326 site to activate HSF1 (Tang, Dai et 
al., 2015). To investigate whether PI3K/AKT signaling activates HSF1 independent of RAS/MEK 
signaling, we examined whether RAS/MEK signaling also affects the phosphorylation of Ser230. We 
incubated recombinant human HSF1 proteins with recombinant active MEK1 or AKT1 proteins in vitro. 
MEK1 phosphorylated HSF1 only at Ser326 site, as detected by the specific pHSF1 Ser326 antibody, and 
AKT1 phosphorylated HSF1 only at Ser230 site in vitro (Fig 5 A). Also, both MK2206 and RG7440 
impaired Ser230, but not Ser326, phosphorylation of HSF1, whereas the MEK inhibitor AZD6244 only 
blocked Ser326 phosphorylation of HSF1 in vivo (Fig 5 B). Both the in vitro and in vivo results highlight 
that AKT1 and MEK1 independently phosphorylated HSF1 at two different sites. Using the HSF1 
reporter system, we discovered that overexpression of constitutively active AKT1 or MEKDD sufficiently 
increased HSF1 activity and overexpression of both AKT1 and MEKDD together had an additive effect on 
activating HSF1 under both heat-shock and non-heat shock conditions (Fig 5 C). In addition, either 
MK2206 or AZD6244 alone suppressed HSF1 activity, whereas a combination of both further inhibited 
HSF1 activity under both HS and non-HS conditions (Fig 5 D). More importantly, overexpression of 
MEK1DD activated HSF1S230A mutants, which cannot be activated by AKT1 (Fig 5 E); and overexpression 
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of AKT1, but not MEKDD, increased the activity of HSF1S326A mutants (Fig 5 E). All these results indicate 
that PI3K/AKT and RAS/MEK signaling pathways regulate HSF1 activation independently. 
 
 
 
 
 
Figure 5. AKT signaling activates HSF1 independent of MEK 
(A) MEK and AKT phosphorylate HSF1 at different sites. 100ng recombinant active AKT1 or MEK1 
proteins were incubated with 400ng recombinant His-HSF1 proteins at RT for 30min. HSF1 
phosphorylation was detected by immunoblotting. Blotting indicated that pHSF1 S230 levels were 
increased when HSF1 proteins were incubated with AKT1 proteins, and pHSF1 S326 levels were 
increased when HSF1 proteins were incubated with MEK1 proteins. 
(B) Inhibition of MEK or AKT decreases HSF1 phosphorylation at different sites. A2058 melanoma cells 
were treated with 20µM AZD6244, 20µM MK2206 or 20µM RG7440 for overnight. Blotting confirmed 
that MK2206 and RG7440 decreased pHSF1 S230 levels, and AZD6244 decreased pHSF1 S326 levels. 
MK: MK2206. RG: RG7440. AZD: AZD6244. 
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Figure 5 continued 
(C) Co-expression of MEK and AKT additively increases HSF1 reporter activities. HEK293T cells were 
co-transfected with the dual HSF1 reporter plasmids and AKT1 or MEKDD plasmids. After 48 hours, cells 
were measured for reporter activities (mean ±SD, n=3 independent experiments, one-way ANOVA). 
Reporter assays confirmed that HSF1 activity was increased in MEKDD- or AKT1-transfected cells, and 
co-expression of both further increased HSF1 reporter activities. 
(D) Combination of AKT and MEK inhibitors additively decreased HSF1 reporter activities under both 
HS and non-HS conditions. HEK293T were transfected with the dual HSF1 reporter plasmids. After 48 
hours cells were treated with 20µM MK2206, 20µM AZD6244, or both for 3 hours followed by HS and 
24-hour recovery with inhibitors. Then cells were measured for reporter activities (mean ±SD, n=3 
independent experiments, one-way ANOVA). Reporter assays confirmed that the HSF1 reporter activity 
was decreased in AZD6244- or MK2206-treated cells, and combination of AKT and MEK inhibitors 
additively decreased HSF1 reporter activities. MK: MK2206. AZD: AZD6244. Non-HS: non-heat shock 
condition. HS: heat shock condition. 
 
 
 
 
LA
CZ
-G
FP
ME
KD
D-L
AC
Z
AK
T1
-LA
CZ
ME
KD
D-A
KT
1
0
1
2
3
4
FO
LD
 C
HA
NG
ES
 O
F 
HS
F1
 R
EP
OR
TE
R 
AC
TI
VI
TY
NS
**** ****
DM
SO
 AZ
D62
44
 MK
220
6
AZD
624
4+M
K22
06
DM
SO
 AZ
D62
44
 MK
220
6
AZD
624
4+M
K22
06
0
2
4
6
FO
LD
 CH
AN
GE
S O
F H
SF
1 R
EP
OR
TE
R A
CT
IVI
TY
NON                                              HS
NS
*
****
**
NS
* *
***
H
SF
1	
re
po
rt
er
LACZ					LACZ			L CZ					 KT1
GFP			 MEKDD AKT1				MEKDD
C
H
SF
1	
re
po
rt
er
DMSO	AZD			MK		AZD+MK				DMSO			AZD			MKAZD+MK
Non-HS																																				HS
D
 45 
Figure 5 continued 
(E) AKT or MEK activates different HSF1 mutants. HSF1-deficient HEK293T cells were transfected 
with the dual HSF1 reporter plasmids and AKT1, MEKDD, HSF1S326A or HSF1S230A plasmids. After 48 
hours, cells were measured for reporter activities (mean ±SD, n=3 independent experiments, one-way 
ANOVA). Reporter assays confirmed that the activity of HSF1S230A was increased by MEKDD expression 
and the activity of HSF1S326A was increased by AKT1 expression. 
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2.3.6 PI3K/AKT Signaling activates HSF1 to support Tissue Overgrowth 
Since PI3K/AKT signaling plays a critical role in controlling cell and tissue growth, we wondered 
whether HSF1 activation could facilitate the PI3K/AKT-driven growth in vivo. To constitutively activate 
PI3K/AKT signaling in vivo, we used R26StopFLP110* mice. These mice express a conditional 
constitutively active PI3KCA allele from the ROSA26 locus. In this conditional allele, a STOP cassette 
flanked by loxP sites prevents the transcription of the constitutively active PI3KCA chimera, p110*, and 
EGFP (Srinivasan, Sasaki et al., 2009) (Fig 6 A). When crossed with Cre deleter mouse strains, this 
p110* allele can be expressed in a tissue-specific manner. In addition to human cancers, activating 
mutations of the components of PI3K/AKT signaling have been implicated in human megalencephaly 
(Riviere, Mirzaa et al., 2012), a developmental disorder characterized by brain overgrowth. As a result, 
patients of megalencephaly have abnormally larger brains than the general population (Mirzaa, Riviere et 
al., 2013). To date, no mouse models for human megalencephaly have been generated. 
To model human megalencephaly and study tissue overgrowth in mice, we crossed R26StopFLP110* mice 
with hGFAP-Cre mice. In this model, expression of the p110* sufficed to drive brain overgrowth, leading 
to rapid demise after birth, since hGFAP-Cre selectively activated PI3K/AKT signaling in multi-potential 
neural stem cells (Zhuo, Theis et al., 2001). To examine the effect of Hsf1 in this model, we further 
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crossed R26StopFLP110* (PI3K p110*) mice with Hsf1fl/fl and hGFAP-Cre mice to produce PI3K p110*+; 
Hsf1+/+;Cre+, PI3K p110*-;Hsf1fl/fl;Cre+, PI3K p110*+;Hsf1fl/fl;Cre+, and PI3K p110*-;Hsf1+/+;Cre+ 
genotypes. So, p110* will be expressed and Hsf1 will be deleted in the same hGFAP- expressing cells, 
including both astrocytes and neurons. PI3K p110*-;Hsf1+/+;Cre+ mice serve as the controls for the effects 
of constitutive activation of PI3K, and these mice have normal brain size (Fig 6 B). PI3K 
p110*+;Hsf1fl/fl;Cre+ and PI3K p110*+;Hsf1+/+;Cre+ mice were tested for the effects of Hsf1 on growth 
driven by constitutively active PI3K. All PI3K p110*+;Hsf1+/+;Cre+ mice developed enlarged brains 
compared to control mice (Fig 6 B). In contrast, PI3K p110*+ mice with homozygous Hsf1 deletion 
showed significantly reduced brain size (Fig 6 B). All these results indicate that Hsf1 is important for cell 
and tissue overgrowth driven by PI3K/AKT signaling.  
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Figure 6. PI3K/AKT signaling activates HSF1 to support tissue overgrowth  
(A) Schematic description of R26StopFLP110* (PI3K p110*) mice, Hsf1fl/fl mice and hGFAP-Cre mice. 
(B) Constitutively active PI3K/AKT signaling drives brain overgrowth. Mouse brains from four distinct 
genotypic groups were compared. Pictures confirmed that PI3K p110*+;Hsf1+/+;Cre+ mice have 
overgrown brains, and deletion of Hsf1 reduced brain size.  
(C) Schematic description of Ptenfl/fl mice, Hsf1fl/fl mice and Albumin-Cre mice. 
(D) Loss of Pten drives liver overgrowth. Livers of mice were compared. Pictures confirmed that 
Ptenfl/fl;Hsf1+/+;Cre+ mice have overgrown livers, and deletion of Hsf1 reduced liver size. 
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Figure 6 continued 
(E) HSF1 suppresses amyloidogenesis induced by constitutively active PI3K/AKT signaling. Amyloid 
fibrils in mouse brains were quantified by ELISA using the OC antibody (mean±SD, n=5 brains, one-way 
ANOVA). ELISA confirmed that PI3K/AKT signaling elevated amyloid fibril levels in the brains, and 
deletion of Hsf1 further increased it. 
(F) HSF1 suppresses cell death in overgrown brains. Caspase 3 activities were detected in mouse brains 
(mean±SD, n=5 brains, one-way ANOVA). Cell death was only detected in Hsf1-deficient overgrown 
brains. 
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Figure 6 continued 
(G) Constitutively active PI3K/AKT signaling drives amyloidogenesis by enhancing protein translation. 
Following treatments with 20µM LY25804702, a potent p70S6K inhibitor, and the pan-caspase inhibitor 
Z-VAD-FMK for overnight, amyloid oligomers and amyloid fibrils were quantitated by ELISA in 
primary astrocytes (mean±SD, n=3 lines of astrocytes, one-way ANOVA). ELISA confirmed that the 
S6K inhibitor decreased amyloid oligomers and fibrils levels in p110*+;Hsf1+/+;Cre+ and 
p110*+;Hsf1fl/fl;Cre+ astrocytes. 
(H) Inhibition of amyloidogenesis reduces cell death. Following treatments with 10µM Congo Red for 
overnight, amyloid fibrils and Caspase 3 activity were quantitated in primary astrocytes (mean±SD, n=3 
lines of astrocytes, one-way ANOVA). ELISA confirmed that Congo red decreased amyloid oligomers 
and fibrils levels in p110*+;Hsf1+/+;Cre+ and p110*+;Hsf1fl/fl;Cre+ astrocytes. Congo red treatment also 
reduced caspase 3 activity in p110*+;Hsf1+/+;Cre+ and p110*+;Hsf1fl/fl;Cre+ astrocytes.  
 
 
 
PI3K
+HS
F1 +
/+ C
RE 
+
PI3K
+HS
F1 l
oxp
/lox
p CR
E+
PI3K
+HS
F1 +
/+ C
RE 
+
PI3K
+HS
F1 l
oxp
/lox
p CR
E+
0.0
0.5
1.0
1.5
2.0
FOL
D C
HAN
GES
 OF
 AM
YLO
ID O
LIG
OM
ER 
LEV
EL
CASPASE INHIBITOR
DMSO                       LY2580472
***
**
****
pi3k
+hsf
1wt 
dms
o
pi3k
+hsf
1-/- 
dms
o
pi3k
+hsf
1wt 
LY25
8740
2
pi3k
+hsf
1-/- 
LY25
8740
20.0
0.5
1.0
1.5
CI
AMY
LOI
D
***
**** ****
PI3K	p110*		+													+													+													+	
Hsf1													+/+								fl/fl +/+								fl/fl
GFAP-Cre +												+													+												+		
PI3K	p110*		+													+													+													+	
Hsf1													+/+								fl/fl +/+									fl/fl
GFAP-Cre +												+													+													+		
DMSO																	LY2584702 DMSO																		LY2584702
Z-VAD-FMK
Fol
d	c
han
ges
	in	
am
ylo
id	
fib
rils
	lev
els
Fol
d	c
han
ges
	in	
am
ylo
id	
olig
om
ers
	lev
els
G
Z-VAD-FMK
PI3
K+
HS
F1 
+/+
 CR
E +
PI3
K+
HS
F1 
lox
p/lo
xp 
CR
E+
PI3
K+
HS
F1 
+/+
 CR
E +
PI3
K+
HS
F1 
lox
p/lo
xp 
CR
E+
0.0
0.5
1.0
1.5
2.0
FO
LD
 CH
AN
GE
S O
F A
MY
LO
ID 
FIB
ER
 LE
VE
L
PBS                          CONGO RED
****
***
****
PI3
K+
HS
F1 
+/+
 CR
E +
PI3
K+
HS
F1 
lox
p/lo
xp 
CR
E+
PI3
K+
HS
F1 
+/+
 CR
E +
PI3
K+
HS
F1 
lox
p/lo
xp 
CR
E+
0
1
2
3
FO
LD
 CH
AN
GE
S O
F C
AS
PA
SE
 3 A
CT
IVI
TY
PBS                                     CONGO RED
NS
*** **
Fol
d	c
han
ges
	in	
cas
pae
3	
act
ivit
y
Fol
d	c
han
ges
	in	
am
ylo
id	
fibr
ils	
lev
els
PI3K	p110*		+									+									+									+	
Hsf1													+/+					fl/fl +/+					fl/fl
GFAP-Cre +									 									+									+		
PI3K	p110*		+										+											+										+	
Hsf1												+/+						fl/fl +/+					fl/fl
GFAP-Cre +										+										+										+		
PBS						CONGO	RED																																							PBS									CONGO	RED
H
 51 
To test the key role of HSF1 activation by AKT in supporting tissue overgrowth, we deleted the tumor 
suppressor Pten to constitutively activate PI3K/AKT signaling. Ptenflox mice possess loxP sites flanking 
exon 5 of the Pten gene. When used in conjunction with a Cre-expressing strain, Pten gene is deleted and 
PI3k/AKT signaling is constitutively activated (Fig 6 C) (Lesche, Groszer et al., 2002). We crossed 
Ptenfl/fl mice with Hsf1fl/fl mice and Albumin-Cre mice to produce Ptenfl/fl;Hsf1+/+;Cre+, 
Pten+/+;Hsf1fl/fl;Cre+, Ptenfl/fl;Hsf1fl/fl;Cre+, and Pten+/+;Hsf1+/+;Cre+ genotypes. The Cre recombinase is 
actively expressed in hepatocytes (Lee, Magnuson et al., 2003). So, PI3K/AKT signaling is constitutively 
activated in hepatocytes. Pten+/+;Hsf1+/+;Cre+ mice serve as the controls (Fig 6 D). Ptenfl/fl;Hsf1fl/fl;Cre+ 
and Ptenfl/fl ;Hsf1+/+;Cre+ mice were tested for the effects of Hsf1 on liver overgrowth in Pten deleted 
background. All Ptenfl/fl;Hsf1+/+;Cre+ mice had enlarged livers compared to the control group (Fig 6 D). 
In contrast, Ptenfl/fl mice with homozygous Hsf1 deletion showed significantly reduced liver size (Fig 6 
D). All these findings confirm that Hsf1 knockout impairs the tissue overgrowth driven by constitutively 
active PI3K/AKT signaling. Since HSF1 is a key player in maintaining proteome homeostasis, we 
wondered whether proteostasis maintained by HSF1 is required for the PI3K/AKT-driven overgrowth. In 
our model, on the one hand PI3K/AKT signaling increases protein quantity through mTOCR1; and on the 
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other hand, PI3K/AKT signaling activates HSF1 to maintain protein quality. We hypothesized that 
deletion of Hsf1 would disrupt the balance between protein quantity and protein quality. To test this 
hypothesis, we first investigated whether proteome is imbalanced by detecting amyloid fibrils in the 
brains of PI3K p110*+;Hsf1+/+;Cre+ mice. Amyloid fibrils are special protein aggregates with highly 
ordered b-sheet structures and are toxic to the cells. The process in which certain misfolded monomeric 
proteins first form intermediate soluble amyloid oligomers, which further assemble into insoluble amyloid 
fibrils, is called amyloidogenesis (Outeiro, 2011). High levels of amyloids indicate severe proteotoxic 
stress and result in cellular toxicity (Ancsin, 2003). We found that, amyloid fibrils were induced in the 
brains of both PI3K p110*+;Hsf1+/+;Cre+ and PI3K p110*+;Hsf1fl/fl;Cre+ mice, and that PI3K 
p110*+;Hsf1fl/fl; Cre+ mice had the highest levels of amyloid fibrils (Fig 6 E). Remarkably, we detected 
elevated Caspase 3 activity only in the brains of PI3K p110*+;Hsf1fl/fl;Cre+ mice mice, (Fig 6 F), which 
indicates that HSF1 suppresses the toxicity caused by amyloidogenesis. To test whether PI3K/AKT 
signaling induces amyloidogenesis by increasing protein translation, we used a potent p70S6K inhibitor, 
LY2584702, to block protein translation in the astrocytes from the PI3K p110*+;Hsf1fl/fl;Cre+ and PI3K 
p110*+;Hsf1+/+;Cre+ mice. LY2584702 inhibits S6K to reduce protein translation (Tolcher, Goldman et 
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al., 2014). Inhibition of translation reduced the levels of amyloid oligomers and amyloid fibrils in both 
astrocytes (Fig 6 G), which indicates that increased protein translation driven by PI3K/AKT signaling 
provokes amyloidogenesis. We used Congo Red, a fluorescence dye selectively binding to amyloid 
structures and preventing amyloid formation (Lorenzo and Yankner, 1994) (Girych, Gorbenko et al., 
2016), to treat the astrocytes from PI3K p110*+;Hsf1fl/fl;Cre+ and PI3K p110*+;Hsf1+/+;Cre+ mice. We 
found decreased levels of amyloid fibrils in both groups, and most importantly, reduced caspase 3 activity 
(Fig 6 H). This result demonstrates a causative role of amyloidogenesis in cell death. All these results 
suggest that HSF1 promotes overgrowth driven by constitutively active PI3K/AKT signaling by 
preventing cell death induced by amyloidogenesis.   
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2.3.7 HSF1 suppresses Amyloidogenesis-induced Cell Death  
How does HSF1 protect cells from the amyloidogenesis-induced toxicity? Since apoptosis is often 
triggered by mitochondrial damage, we wondered whether the astrocytes from PI3K p110*+;Hsf1fl/fl;Cre+ 
mice had increased apoptosis due to mitochondrial damage. We observed elevated levels of poly-
ubiquitinated proteins and decreased levels of the mitochondrial marker TOMM20 proteins, which 
indicate mitochondrial damage in these astrocytes (Fig 7 A). Also, the localization of HSP60, the key 
chaperone in the mitochondria, was significantly altered in these astrocytes. HSP60 showed diffused 
staining into both the cytoplasm and nuclei in the astrocytes from PI3K p110*+;Hsf1fl/fl;Cre+ mice (Fig 7 
A B). In addition, we found small foci of HSP60 in these astrocytes (Fig 7 B), which suggests HSP60 
aggregation. To further verify HSP60 aggregation, we detected HSP60 levels in the detergent-soluble and 
-insoluble fractions of the mouse brain lysates.   
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Figure 7. HSF1 suppresses amyloidogenesis-induced cell death by preventing HSP60 from aggregating 
(A) Mitochondria are damaged in PI3K p110*+;Hsf1fl/fl;Cre+ astrocytes. Proteins were detected by 
immunoblotting in astrocytes after both mitochondrial and cytoplasmic fractions were separated. Blotting 
confirmed that elevated levels of poly-ubiquitinated proteins and PARKIN proteins, decreased levels of 
TOMM20 proteins in the mitochondrial fractions and that HSP60 and cytochrome C translocated from 
the mitochondria to the cytoplasm. MITO: mitochondrial fraction. CYTO: cytoplasmic fraction. 
(D) Loss of soluble HSP60 proteins is not due to transcriptional regulation. Hsp60 mRNA levels in brains 
were quantitated by qRT-PCR (mean±SD, n=5 brains, one-way ANOVA). qRT-PCR confirmed that 
Hsp60 mRNA level had no significant differences among four genotypic groups of mice.   
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Figure 7 continued 
(B) Hsf1 deficiency changes HSP60 localization pattern in PI3K p110*+;Hsf1fl/fl;Cre+ astrocytes. 
Astrocytes were stained with anti-HSP60 antibodies. Arrowheads mark HSP60 foci. IF staining 
confirmed that HSP60 diffused from the mitochondria into the cytoplasm in the astrocytes from PI3K 
p110*+;Hsf1fl/fl;Cre+ mice. Scale bar is 10µm.  
(C) HSF1 prevents HSP60 aggregation in PI3K p110*-expressing mouse brains. Proteins were detected 
by immunoblotting in detergent-soluble and -insoluble fractions of mouse brain tissues. Blotting 
confirmed that TOMM20 levels were decreased in the brains of PI3K p110*+;Hsf1fl/fl;Cre+ mice 
compared to the other groups, and HSP60 levels were decreased in the detergent-soluble fractions and 
increased in the detergent-insoluble fractions of the brain tissues of PI3K p110*+;Hsf1fl/fl;Cre+ mice. 
SOLUBLE: soluble fraction. INSOLUBLE: insoluble fraction.  
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Figure 7 continued 
(E) Loss of HSP60 causes mitochondrial damage. Proteins were detected by immunoblotting in astrocytes 
transfected with siRNAs targeting Hsp60 after the mitochondrial and cytoplasmic fractions were 
separated. Blotting confirmed that knocking down Hsp60 in PI3K p110*+;Hsf1+/+;Cre+ astrocytes 
elevated poly-ubiquitinated proteins and PARKIN and decreased TOMM20 proteins in the mitochondrial 
fractions, and caused HSP60 and cytochrome C to translocte from the mitochondria to the cytoplasm. 
MITO: mitochondrial fraction. CYTO: cytoplasmic fraction.   
(F) Loss of HSP60 causes apoptosis. Caspase 3 activities were detected in astrocytes transfected with 
siRNAs targeting Hsp60. Caspase 3 activities confirmed that knocking down Hsp60 in 
p110*+;Hsf1+/+;Cre+ astrocytes induced cell death. 
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Figure 7 continued 
(G) Amyloid oligomer (AO) physically interacts with HSP60. Endogenous AO-HSP60 interactions were 
detected by PLA in astrocytes using a rabbit anti-AO antibody and a mouse anti-HSP60 antibody. PLA 
staining confirmed that there is a physical association between AO and HSP60 only in PI3K 
p110*+;Hsf1fl/fl;Cre+ astrocytes. Scale bar is 10µm. 
(H) Amyloid oligomer (AO) physically interacts with HSP60. Endogenous HSP60 proteins were 
precipitated from brain lysates using the specific anti-AO antibody. WCL: whole cell lysate. Blotting 
confirmed that there is a physical association between AOs and HSP60 only in PI3K p110*+;Hsf1fl/fl;Cre+ 
brains.  
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Figure 7 continued 
(I) Overexpression of HSP60 rescues mitochondrial damage in PI3K p110*+;Hsf1fl/fl;Cre+ astrocytes. 
Proteins were detected by immunoblotting in astrocytes transduced with lentiviral LACZ or HSP60 after 
the mitochondrial and cytoplasmic fractions were separated. Blotting confirmed that overexpression of 
HSP60 decreased poly-ubiquitinated proteins and PARKIN but increased TOMM20 proteins in the 
mitochondrial fraction, and prevented HSP60 and cytochrome C from translocating to the cytoplasm. 
MITO: mitochondrial fraction. CYTO: cytoplasmic fraction.   
(J) Overexpression of HSP60 rescues cell death in PI3K p110*+;Hsf1fl/fl;Cre+ astrocytes. Caspase 3 
activities were detected in astrocytes transduced with lentiviral LACZ or HSP60. Caspase 3 activities 
confirmed that overexpression of HSP60 in PI3K p110*+;Hsf1fl/fl;Cre+ astrocytes prevented cell death.  
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Figure 7 continued 
(K) HSF1 prevents the HSP60-AO interactions. Endogenous AO-Hsp60 interactions and AO-HSF1 
interactions were detected by PLA in astrocytes using a rabbit anti-AO antibody (A11), a mouse anti-
HSP60 antibody and a mouse anti-HSF1 antibody. PLA staining confirmed that HSF1WT and N-terminus 
mutants (HSF11-379), but not C- terminus mutants (HSF1380-529), blocked the interaction between HSP60 
and AOs, and HSF1WT and N-terminus mutants (HSF11-379), but not C- terminus mutants (HSF1380-529), 
directly interacted with AOs. Scale bar is 10µm. 
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Figure 7 continued 
(L) HSF1 prevents HSP60 aggregation induced by Ab amyloids in vitro. Recombinant human HSP60 
proteins were incubated with Aβ1-42 or 42-1 Aβ42-1 peptides in the presence of recombinant GST or human 
His-HSF1 proteins. Following shaking at 370C for 72 hours and centrifugation, proteins were detected by 
immunoblotting in the supernatants and pellets. Blotting confirmed that HSP60 aggregation caused by 
Ab1-42 peptides was blocked by recombinant HSF1 proteins.  
(M) Schematic description of the protection of mitochondria from amyloids by HSF1. Under proteotoxic 
stress conditions, in Hsf1-proficient cells amyloid oligomers interact with HSF1, instead of HSP60, in the 
mitochondria; so HSP60 can function as a major chaperone to maintain mitochondrial proteome 
homeostasis. However, in Hsf1-deficient cells, amyloid oligomers directly attack HSP60 in the 
mitochondria to cause its aggregation, leading to misfolding and aggregation of other mitochondrial 
proteins, which finally induces mitochondrial damage and apoptosis.  
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Consistent with the finding in astrocytes, TOMM20 levels were decreased in the brain tissues of PI3K 
p110*+;Hsf1fl/fl;Cre+ mice compared to the other groups (Fig 7 C), which confirmed mitochondrial 
damage. Strikingly, HSP60 levels decreased in the soluble fractions but increased in the insoluble 
fractions of the brain tissues of PI3K p110*+;Hsf1fl/fl;Cre+ mice (Fig 7 C), although no significant changes 
were detected in Hsp60 mRNA levels (Fig 7 D). These results indicate that loss of HSP60 proteins in the 
brains of PI3K p110*+;Hsf1fl/fl;Cre+ mice was due to HSP60 aggregation. Knockdown of Hsp60 in the 
PI3K p110*-;Hsf1+/+;Cre+ astrocytes mimicked the phenotypes of the PI3K p110*+;Hsf1fl/fl;Cre+ 
astrocytes, which resulted in increased poly-ubiquitinated proteins and decreased TOMM20 proteins in 
the mitochondria, translocation of HSP60 from the mitochondria to the cytoplasm, and elevated Caspase 3 
activities (Fig 7 E F). In addition, restoration of HSP60 levels in the PI3K p110*+;Hsf1fl/fl;Cre+ astrocytes 
rescued mitochondrial damage and cell death, indicated by reduced poly-ubiquitinated proteins and 
increased TOMM20 proteins in the mitochondria, and reduced caspase 3 activities (Fig 7 I J). These 
results establish the causative role of HSP60 loss in mitochondrial damage and cell death. To further 
dissect how HSP60 aggregation is induced, we investigated the possibility that amyloid oligomers (AOs) 
directly interacts with HSP60 proteins using both PLA and CoIP. HSP60 directly binds to AOs in the 
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astrocytes and brain tissues from PI3K p110*+;Hsf1fl/fl;Cre+ mice (Fig 7 G H). These results suggest that 
HSF1 protects HSP60 from interacting with AOs. Next, we investigated how HSF1 prevents HSP60 
aggregation by over-expressing HSF1 wide-type (HSF1WT), HSF1 N-terminus mutants (HSF11-379), which 
lack the transactivation domain, and HSF1 C-terminus mutants (HSF1380-529), which lack the DNA 
binding domain, in both PI3K p110*+;Hsf1fl/fl;Cre+ and PI3K p110*+;Hsf1+/+;Cre+ astrocytes. Expression 
of HSF1 wide-type (HSF1WT) and N-terminus mutants (HSF11-379), but not C-terminus mutants (HSF1380-
529), in the PI3K p110*+;Hsf1fl/fl;Cre+ astrocytes blocked the interactions between HSP60 and AOs (Fig 7 
K). Importantly, HSF1 wide-type (HSF1WT) and N-terminus mutants (HSF11-379) directly interacted with 
AOs, instead of HSP60 (Fig 7 K). These results strongly suggest that HSF1 protects HSP60 from 
aggregation through physical interactions. In addition, recombinant HSF1 proteins prevented the 
aggregation of recombinant HSP60 proteins induced by Aβ1-42 amyloid peptides in vitro (Fig 7 L). So, our 
results indicate that HSF1 protects cell from the amyloidogenesis-induced toxicity by preventing HSP60 
aggregation and maintaining the mitochondrial proteome homeostasis (Fig 7 M). 
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2.4 Discussion 
2.4.1 HSF1 is a New Physiological Substrate of AKT 
Our studies now show that AKT directly phosphorylates HSF1 at Ser230 site. Previously, we discovered 
that the oncoprotein MEK directly phosphorylates HSF1 at Ser326 site. Although both phosphorylation 
events activate HSF1, the underlying mechanisms are different. While the MEK-mediated Ser326 
phosphorylation promotes HSF1 nuclear translocation and DNA binding, the AKT-mediated Ser230 
phosphorylation does not affect this process and only enhances its DNA binding. These distinct effects 
are consistent with the observation that both phosphorylation events are independent of each other and 
activate HSF1 in an additive manner. Our findings also suggest HSF1 could be activated through 
phosphorylation by separate oncogenic pathways in different tumors. However, whether other oncogenic 
signaling can regulate HSF1 through other mechanism, such as nuclear translocation and trimerization, is 
still a big question worth to explore in the future. 
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2.4.2 AKT drives Growth by coordinating Protein Quantity- and Quality-control Machineries 
As a key player in growth control, AKT appears to govern two discrete but well-coordinated downstream 
effector pathways, of which one is mediated by HSF1 to control protein quality and the other by 
mTORC1 to control protein quantity. On the one hand, constitutively active PI3K/AKT signaling 
provokes proteomic chaos by markedly increasing protein quantity through mTORC1, and on the other 
hand, through HSF1 activation, PI3K/AKT signaling heightens cellular chaperoning capacity to ensure 
productive protein synthesis. Balanced protein quantity and quality leads to proteostasis and robust 
growth. This is supported by our observation that deletion of Hsf1 disrupts proteostasis and impairs tissue 
overgrowth driven by constitutive activation of PI3K/AKT signaling. Interestingly, our study is the first 
one to report constitutively active PI3K/AKT signaling can maintain proteome homeostasis through 
activating HSF1. However, there are many other effectors mediating proteome homeostasis, such as 
proteasome pathways, autophagy pathways and unfolded protein response (UPR) pathways. So, it will be 
exciting to investigate whether constitutively active PI3K/AKT signaling can regulate any of these 
pathways to maintain proteome homeostasis in the future.  
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2.4.3 Guarding of Mitochondrial Proteostasis by HSF1 through Prevention of HSP60 Aggregation 
Our findings uncover a new role of HSF1 in regulating mitochondrial proteostasis to promote overgrowth, 
which is independent of its transcriptional function. One of the key consequences of disruption of 
proteostasis is the emergence of amyloids. It has been widely recognized that amyloids are toxic to the 
cells, particularly neurons. Although many mechanisms by which amyloids induce neurotoxicity have 
been proposed, the precise direct molecular targets of amyloids underlying neurotoxicity has remained 
controversial. Our data supports that soluble amyloid oligomers are the primary inducer of cellular 
toxicity. In addition, our study provides a new theory of how soluble amyloid oligomers induce cellular 
toxicity. In the absence of HSF1, amyloid oligomers directly induce aggregation of HSP60, which 
ultimately leads to mitochondrial damage and cell death. We also think that this could be the same 
mechanism of how amyloidogenesis induce tumor cells death when HSF1 is diminished and proteome 
homeostasis is disrupted in tumors. Furthermore, we unveiled that HSF1 can suppress amyloid formation 
through physical interaction, which has a great therapeutic potential to treat amyloid diseases in humans 
in the future.  
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2.5 Experimental Procedures 
2.5.1 Cells and Tissues 
HEK293T, HeLa, A2058 cells were purchased from ATCC. Primary astrocytes were directly derived 
from neonatal mouse brains. All cells were cultured in DMEM supplemented with 10% fetal bovine 
serum. Brain and liver tissues were directly derived from mice and stored in -80oC. 
2.5.2 Proximity Ligation Assay 
Cells were fixed with 4% formaldehyde in PBS for 15 minutes at room temperature and blocked with 5% 
normal goat serum in PBS with 0.3% Triton X-100. Primary antibodies were 1:100 diluted in blocking 
buffer and used to incubate fixed cells overnight at 4°C. After incubation with Duolink PLA anti-rabbit 
Plus and anti-mouse Minus probes (1:5, OLINK Bioscience) at 37°C for 1 hour, ligation for 0.5 hour and 
amplification for 110 minutes, Nuclei were stained with Hoechst 33342. Then PLA signals were 
documented by a Zeiss 780 confocal microscope or quantified by flow cytometry. 
2.5.3 Real-time Quantitative RT–PCR 
Total RNAs were extracted using RNA STAT-60 reagent (Tel-Test), and RNAs were reverse transcripted 
using a High Capacity Reverse Transcription kit (Applied Biosystems). Equal amounts of cDNAs were 
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used for quantitative RCR reaction using a DyNAmo SYBR Green qPCR kit (Thermo Scientific). Signals 
were detected by an ABI 7500 Real-Time PCR System (Applied Biosystems) and Stratagene Mx3000P 
real-time PCR System (Applied Biosystems). ACTB and 18S were used as the internal control.  
2.5.4 Transfection and Luciferase Reporter Assay 
TurboFect transfection reagent (Thermo Scientific) was used to transfect plasmids. The Ziva Ultra SEAP 
Plus Detection Kit (Jaden BioScience) was used to detect SEAP activities in culture supernatants while 
the Gaussia Luciferase Glow Assay Kit (Thermo Scientific) was used to detect Guassia luciferase 
activities. VICTOR3 Multilabel plate reader (PerkinElmer) was used to measure the luminescence. 
2.5.5 Cell Apoptosis Assay 
A caspase 3 DEVD-R110 Fluorometric and Colorimetric Assay kit (Biotium) was used to detect caspase 
3 activity. 
2.5.6 Measurement of Liver Cell Size 
Mouse liver cells were mechanically dissociated in PBS containing 10% FBS. Livers were squeezed 
through a 70mm nylon cell strainers by a syringe head. After collecting single-cell suspensions by 
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centrifuging at 500g for 5 min, cells were washed three times with PBS–FBS and analyzed by flow 
cytometry. The primary cell populations were gated for size measurement based on forward scatter. 
2.5.7 shRNA and siRNA Knockdown 
Lentiviral pLKO shRNA plasmids targeting human PTEN were obtained from Addgene. MISSION 
siRNAs: HSPD1 were purchased from Sigma-Aldrich. The non-targeting siRNA control (D-001810-01) 
was purchased from Dharmacon GE Healthcare. 
2.5.8 In vitro Kinase Assay 
100 ng HSF1 proteins were incubated with 30µl kinase buffer (25mM MOPS pH 7.2, 12.5mM β-glycerol-
phosphate, 25mM MgCl2, 5mM EGTA, 2mM EDTA, 0.25mM dithiothreitol, 250µM ATP) and 100 ng 
recombinant GST, AKT1, AKT2, AKT3, MEK1, CaMKII or DAPK active proteins (SignalChem) at 
30°C for 30 minutes with 1,200 r.p.m. mixing in an Eppendorf ThermoMixer. Reactions were stopped by 
adding 20µl 2× sample buffer with 3% 2-mercaptoethanol. 
2.5.9 Animal Studies 
R26StopFLP110* (PI3K p110*) mice, Hsf1fl/fl mice, hGFAP-Cre mice, Ptenfl/fl mice and Albumin-Cre mice 
on the C57BL/6 background were obtained from The Jackson Laboratory. R26StopFLP110* (PI3K p110*) 
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mice were crossed with Hsf1fl/fl mice and hGFAP-Cre mice to produce PI3K p110*+;Hsf1fl/fl;Cre+, PI3K 
p110*+;Hsf1+/+; Cre+, PI3K p110*-;Hsf1fl/fl;Cre+ and PI3K p110*-;Hsf1+/+;Cre+ genotypes. Ptenfl/fl mice 
were crossed with Hsf1fl/fl mice and Albumin-Cre mice to produce Ptenfl/fl;Hsf1fl/fl;Cre+, Ptenfl/fl; 
Hsf1+/+;Cre+, Pten+/+Hsf1fl/fl; Cre+ and Pten+/+;Hsf1+/+;Cre+ genotypes. Genotyping was performed by 
PCR using tail genomic DNAs. All mouse experiments were performed under protocol approved by both 
The Jackson Laboratory Animal Care and Use Committee and NCI Animal Care and Use Committee. 
2.5.10 Immunofluorescence 
Cultured cells were seeded on the slides and fixed with 4% formaldehyde for 15 minutes RT, then 
blocked with blocking buffer for 1 hour. 1:100 primary antibodies were applied to the slides and 
incubated at 40C overnight. 1:200 secondary antibodies were applied and incubated at RT for 1 hour. 
Fluorescent signals were captured by a Zeiss 780 confocal microscope and the images were analyzed with 
ImageJ software. 
2.5.11 Detergent-soluble and -insoluble Fractionation 
Equal numbers of cells were incubated with cell lysis buffer containing 1% Triton X-100 on ice for 
20 minutes. The crude lysates were first centrifuged at 500 g for 5 min at 4°C. The supernatants were 
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collected as 1st supernatants. The pallets were digested with DNase I at RT for 20 minutes then further 
incubated with 50µl 2% SDS at RT for 30 minutes and centrifuged at max speed for 10 minutes at RT. 
The supernatants were collected as membrane fractions. Pellets were mixed with 1st supernatants and 
centrifuged at max speed at 4°C for 10 minutes. The supernatants were collected as soluble fractions and 
the pellets as insoluble fractions, which were further subjected to sonication for SDS–PAGE or ELISA. 
2.5.12 Amyloid Oligomer and Fibril Quantitation by ELISA 
Equal amount of proteins (20µg) from soluble fraction were incubated in each well of a 96 wells ELISA 
plate in a total volume of 100µl at 4 0 C overnight. 100µl milk was used as blocking buffer to each wells 
and incubated at RT for 1 hour. 100µl milk containing oligomer antibodies (A11, 1:1000) was applied to 
each well at RT for 2 hours as primary antibody. Then 100µl milk containing secondary antibodies 
(rabbit, 1: 5000) was applied to each well and incubated at RT for 1 hour. 100µl 1-step Ultra TMB-
ELISA was used as detection reagent. The ELISA signals were finally captured by spectraMAX 190. 
After quantification of proteins from insoluble fractions, equal amount of proteins was added to each well 
a 96 wells ELISA plate in a total volume of 100µl and incubated at 37°C without cover overnight to dry 
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the wells. The following steps were the same as the detection of amyloid oligomer except that primary 
antibodies for amyloid fibril are amyloid fibril antibodies (OC). 
2.5.13 Statistics Analysis 
Prism 6.0 (GraphPad software) was used to analyze the results. Two groups were compared by Unpaired 
two-tailed Student’s t-test. Multiple groups were compared by one-way or two-way ANOVA. All samples 
and animals were included in the analyses.  
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CHAPTER 3 
 CONCLUSION AND FUTURE WORK 
3.1 HSF1 is a New Physiological Target of AKT Kinase 
PI3K/AKT signaling cascade is essential to cell growth and differentiation. Activated by growth factors, 
PI3K phosphorylates PIP2 to PIP3, which further phosphorylates PDK1. PDK1 phosphorylating AKT at 
T308 site at the cellular membrane leads to AKT partial activation. AKT is fully activated by mTORC2 
through phosphorylation of S473 site (Guo, Tian et al., 2017). Upon activation, AKT can enter the 
nucleus to phosphorylate many downstream targets. Hundreds of proteins have been identified as AKT 
targets including TSC2, FoxO proteins and GSK3. AKT activates mTOCR1 through phosphorylating and 
inhibiting TSC2, which enables cell growth (Makker, Goel et al., 2014). In addition, AKT phosphorylates 
FoxO proteins, leading FoxO proteins out of the nucleus, which suppresses FoxO transcriptional program 
involved in the induction of apoptosis, cell cycle arrest, catabolism and growth inhibition (Atfi, Abecassis 
et al., 2005). Also, AKT is part of the growth factor signaling that mediates GSK3 phosphorylation 
(Hermida, Dinesh Kumar et al., 2017). Thus, AKT functions as a critical mediator for cell growth and 
survival through multiple interconnected pathways.  
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In our current study, we, for the first time, identified HSF1 as a target of AKT. Through in vivo and in 
vitro experiments, we found that AKT phosphorylates HSF1 at S230 site, which is an important 
modification during HSF1 activation. Phosphorylation of HSF1 S230 site is necessary to promote HSF1 
activation. According to our results, HSF1 S230A mutants still exhibited certain levels of transcriptional 
activity and can be further activated by another oncoprotein MEK, which indicates that multiple signaling 
pathways regulate HSF1 activation through distinct phosphorylation sites independently. So far, we have 
discovered that HSF1 activity is regulated by tumor-suppressive AMPK signaling, oncogenic RAS/MEK 
and PI3K/AKT signaling. These findings suggest that HSF1 could be constitutively activated through 
distinct mechanisms in different tumors, depending on which mutations are present. Furthermore, there 
could be other oncogenic or tumor-suppressive pathways regulating HSF1, which is worth exploring in 
the future. 
In this study, we found that Ser230 phosphorylation by AKT promotes HSF1 DNA binding but not its 
nuclear translocation. Regarding the process of HSF1 activation, however, there is an interesting question 
we have not answered in this project. Does this phosphorylation affect HSF1 trimerization? HSF1 
 75 
trimerization is an indispensable step for its activation. However, the pathways regulating this step still 
remain elusive. So far, one study suggests that HSF1 trimerization is temperature-inducible (Hentze, Le 
Breton et al., 2016). It will be interesting to investigate in the future whether HSF1 is prone to forming 
trimers in tumor cells or whether HSF1 trimerization is promoted by oncogenic pathways such as 
PI3K/AKT or RAS/MEK signaling.   
Constitutively activated PI3K/AKT signaling mobilizes HSF1 to guard against proteotoxic stress induced 
by protein overproduction driven by hyper-activated mTORC1. In our study, AKT governs both protein 
quantity- and quality-control machineries through mTOCR1 and HSF1, respectively. While it has been 
known that AKT regulates cell growth through many interconnected pathways such as mTOCR1, FoxO 
proteins and GSK3, it is discovered for the first time that AKT is directly involved in regulating 
proteomic quality. As mentioned before, proteotstasis is regulated by a network of pathways. So, we 
wonder whether PI3K/AKT pathway can protect proteostasis through other pathways besides HSF1. It 
was noted that PI3K/AKT signaling is activated during endoplasmic reticulum (ER) stress caused by 
accumulation of misfolded proteins inside ER. Thus, it would be interesting to investigate whether 
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PI3K/AKT signaling can activate the unfolded protein response (UPR), a key mechanism that fights 
against ER stress particularly, in the future.  
3.2 A Mouse Model for Human Megalencephaly 
Loss of PTEN through somatic mutations have been found in many human cancers (Gu, Ou et al., 2016) 
(Alimonti, 2010). Furthermore, activating mutations of PI3K and AKT have also been identified in 
human tumors (Samuels and Waldman, 2010) (Karakas, Bachman et al., 2006) (Yi and Lauring, 2016). 
Thus, hyper-activated PI3K/AKT signaling is considered as an attractive anti-cancer therapeutic target 
(Pal and Mandal, 2012) (Zhang, Jin et al., 2007). So far, many mouse models in which the PI3K/AKT 
signaling pathway is genetically modified have been generated to study tumorigenesis and tumor 
progression. For instance, Pten+/- mice develop tumors in multiple tissues, including the breast, 
endometrium and prostate, which demonstrate many features found in corresponding human cancers 
(Knobbe, Lapin et al., 2008). Transgenic mice carrying the PI3KCA-H1047R or PI3KCA-E545K mutation 
under the control of mammary gland-specific promoter developed breast cancer showing basal and 
luminal markers (Meyer, Koren et al., 2013). Expressing the PI3KCA-H1047R mutant in the lungs 
induced lung adenocarcinomas (Green, Trejo et al., 2015).  
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Although the PI3K/AKT signaling pathway is activated in 90% human glioblastomas, no mouse 
glioblastoma models carrying constitutively active PI3KCA or AKT mutations exist (Carnero and 
Paramio, 2014). So, in the beginning of our project, we set out to tackle this challenge, by activating 
PI3K/AKT signaling in neural progenitor cells, which can differentiate into both glia and neurons. 
Strikingly, instead of developing brain tumors, these mice showed enlarged brains and died within 20 
days after birth. We suspected that these mice probably lived too short to develop tumors, which is 
probably due to the massive expression of p110* in the brain. So, we propose alternative strategies to 
generate a glioblastoma mouse model by crossing R26StopFLP110* mice with GFAP-CreERT2 mice. Then, 
we can deliver tamoxifen into the brains through intracranial injections. It is a promising strategy that has 
been used to generate mouse models of glioblastoma expressing other oncogenes previously (Lenting, 
Verhaak et al., 2017).  
Although the mice in our study did not develop glioblastomas, they indeed displayed the phenotypes 
resembling human megalencephaly. Megalencephaly is a developmental disorder characterized by brain 
overgrowth. Recent genetic studies have revealed that megalencephaly in human is caused by activating 
mutations of the components of PI3K/AKT signaling (Riviere, Mirzaa et al., 2012). Patients of 
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megalencephaly have abnormally large brains that are 2.5 standard deviations above the general 
population (Mirzaa, Riviere et al., 2013). To our knowledge, our hGFAP-Cre; R26StopFLP110* mice are 
the first mouse model of megalencephaly that recapitulates the same genetic alterations in humans. In 
addition, our mouse model can be used to test the potential treatments for this disease. In our current 
study, deletion of Hsf1 reduced brain size and prolonged mice lifespan, which is due to increased cell 
death caused by severe proteotoxic stress. Interestingly, in our previous study, we showed that the 
combination of MEK and proteasome inhibition inactivated HSF1 in tumor cells, which leads to severe 
proteotoxic stress and cell death. Thus, we speculated that treatment of the megalencephaly mice with 
combined MEK and proteasome inhibitors may alleviate the symptoms and prolong their lifespans. 
Apparently, more work is needed to test our hypothesis in the future. Another important direction for our 
future work is to verify the key findings in the mouse models using patient tissues. We would like to get 
some brain tissues from both healthy people and patients with megalencephaly. We are very interested in 
investigating whether disruption of proteostaiss, evidenced by elevated protein polyubiqitination and 
amyloidogenesis, and HSF1 activation are associated with human megalencephaly.  
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3.3 HSF1 suppresses Amyloidogenesis through Physical Interaction 
Amyloidogenesis is a process in which specific proteins converse from their native soluble functional 
states into highly ordered filamentous amyloid fibrils (Tycko, 2014). Amyloidogenesis is associated with 
a number of neurodegenerative disorders. In each of these pathological conditions, a particular protein 
first convert from its native, functional state into small intermediates – soluble amyloid oligomers, and 
further into insoluble amyloid fibrils with enriched b-sheet structures (Tofoleanu and Buchete, 2012). 
Interestingly, amyloid oligomers or amyloid fibrils formed by proteins or peptides with discrete amino 
acid sequences share a common conformation that can be recognized specifically by antibodies (Kayed, 
Head et al., 2007). So far, more than 20 proteins, that can form amyloid oligomers and amyloid fibrils 
under certain human pathological conditions, have been identified (Chiti and Dobson, 2017). In our study, 
we found that in the mouse model of megalencephaly, amyloidogenesis is elevated in the overgrown 
brains. We further showed that PI3K/AKT signaling induced amyloidogenesis by enhancing the 
mTORC1-meditaed protein translation. In contrast, amyloidogenesis has not been associated with 
megalencephaly and the identifications of these amyloids remain unknown. Thus, in the future work, we 
will address this question using the brain samples from both our mouse models and human 
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megalencephaly patients. Following immunoprecipitating amyloid oligomers using the amyloid 
conformation-specific antibody A11, the potential amyloids can be identified by mass spectrometry.  
Clearly, amyloidogenesis can lead to cell death. However, whether soluble amyloid oligomers or 
insoluble amyloid fibrils are the primary inducer of cellular toxicity remains uncertain. Early research 
focusing on Alzheimer’s disease suggested that large amyloid fibrils cause neuronal cell death and disease 
pathology. However, over the years, researchers found that in Alzheimer’s disease, there was no 
correlation between Ab amyloid fibrils deposition and the severity of this disease (Ow and Dunstan, 
2014). Instead, the levels of soluble Ab oligomers in the brains of patients of Alzheimer’s disease were 
found to be correlated with cognitive impairment in several studies (Hayden and Teplow, 2013) 
(Benilova, Karran et al., 2012) (Viola and Klein, 2015). Furthermore, in the case of Parkinson disease, 
injection of a-synuclein oligomers, but not a-synuclein fibrils, caused neuronal cell death (Winner, 
Jappelli et al., 2011). These findings together suggest that soluble amyloid oligomers are the real culprit 
leading to cellular toxicity. To date, two mechanisms have been proposed for how soluble amyloid 
oligomers induce cellular toxicity. One group suggested that Ab oligomers damage the lipid bilayer of the 
cellular membrane by affecting phospholipid composition and negative charges (Canale, Seghezza et al., 
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2013). The other study pointed out that amyloid oligomers ubiquitously elevated intracellular Ca2+ levels, 
which leads to toxicity and elicits downstream pathological events (Demuro, Mina et al., 2005) (Mattson, 
Cheng et al., 1992). In contrast, our study unveiled an entirely new model. In the absence of HSF1, 
amyloid oligomers directly induce aggregation of HSP60, an essential mitochondrial chaperone, which 
causes disruption of mitochondrial proteostasis that ultimately leads to mitochondrial damage and cell 
death. In our previous study, we demonstrated that amyloidogenesis caused by the combination of MEK 
and proteasome inhibitors induce apoptosis in tumor cells. However, we had not elucidated the 
mechanisms at that time. According to our new findings, we hypothesize that it may be the same 
mechanism we uncovered in the overgrown brains. To test this, in future work, we plan to study whether 
amyloid oligomers binds to HSP60 after combined treatment of MEK and proteasome inhibitors in tumor 
cells.  
Of note, there is no approved therapeutic reagents to target amyloids although several designed peptides 
and small polyphenol molecules have been demonstrated to inhibit the assembly of amyloid fibrils (Porat, 
Abramowitz et al., 2006) (Martins, 2013) (Zraika, Aston-Mourney et al., 2010). In our study, we 
discovered for the first time that a transcription factor – HSF1 – can directly interact with amyloid 
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oligomers and markedly suppress the formation of amyloid fibrils. Importantly, HSF1 blocks 
amyloidogenesis independent of its transcription activity. In addition to guarding proteostasis by 
upregulating the expression of molecular chaperones, HSF1 directly binds to amyloid oligomers, which 
not only prevents amyloid oligomers assembling into amyloid fibrils but also protects other essential 
proteins such as HSP60 from the direct attack by amyloids. This novel function of HSF1 has not been 
discovered previously. Our studies suggest that HSF1 could be exploited to treat amyloid diseases such as 
Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS). 
While much effort has been focused on identifying HSF1 activators, which can improve proteostasis by 
inducing the transcription of HSPs, the anti-amyloid effect of HSF1 through physical interactions has not 
been exploited. In another ongoing project of ours, we screened a HSF1 peptide library and found that 
several HSF1 peptides are able to block the assembly of amyloid fibrils. Thus, these peptides may have a 
great therapeutic potential to treat amyloid diseases in humans.  
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